{"id":"https://openalex.org/W2011753619","doi":"https://doi.org/10.1310/rrx7-49me-27v7-mwwv","title":"Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers","display_name":"Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers","alternate_titles":[],"publication_year":2004,"publication_date":"2004-12-01","ids":{"openalex":"https://openalex.org/W2011753619","doi":"https://doi.org/10.1310/rrx7-49me-27v7-mwwv","mag":"2011753619","pmid":"https://pubmed.ncbi.nlm.nih.gov/15682350"},"language":"en","primary_location":{"id":"doi:10.1310/rrx7-49me-27v7-mwwv","doi":"https://doi.org/10.1310/rrx7-49me-27v7-mwwv","is_oa":true,"landing_page_url":"https://doi.org/10.1310/rrx7-49me-27v7-mwwv","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1310/RRX7-49ME-27V7-MWWV?needAccess=true&role=button","source":{"id":"https://openalex.org/S13415641","display_name":"HIV Clinical Trials","issn_l":"1528-4336","issn":["1528-4336","1945-5771"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV Clinical Trials","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2011753619"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.1310/RRX7-49ME-27V7-MWWV?needAccess=true&role=button","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045416293","display_name":"Thomas R. MacGregor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Thomas R. MacGregor","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877, USA. tmacgreg@rdg.boehringer-ingelheim.com","Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877, USA. tmacgreg@rdg.boehringer-ingelheim.com","institution_ids":["https://openalex.org/I4210160255"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063224526","display_name":"John P. Sabo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John P. Sabo","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060735489","display_name":"Stephen H. Norris","orcid":"https://orcid.org/0009-0009-7323-4629","observed_orcids":["https://orcid.org/0009-0009-7323-4629"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephen H. Norris","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053392771","display_name":"Philip A. Johnson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Philip Johnson","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036037842","display_name":"Lawrence Galitz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lawrence Galitz","raw_affiliation_strings":["South Florida Bioavailability Clinic, Miami, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Florida Bioavailability Clinic, Miami, Florida, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033836920","display_name":"Scott H. McCallister","orcid":"https://orcid.org/0000-0002-2536-3188","observed_orcids":["https://orcid.org/0000-0002-2536-3188"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Scott McCallister","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut","institution_ids":["https://openalex.org/I4210160255"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5045416293"],"corresponding_institution_ids":["https://openalex.org/I4210160255"],"apc_list":null,"apc_paid":null,"fwci":4.2388,"has_fulltext":true,"cited_by_count":63,"citation_normalized_percentile":{"value":0.93934123,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":96},"biblio":{"volume":"5","issue":"6","first_page":"371","last_page":"382"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9023000001907349,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9023000001907349,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.042899999767541885,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.010300000198185444,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tipranavir","display_name":"tipranavir","score":1.0},{"id":"https://openalex.org/keywords/ritonavir","display_name":"ritonavir","score":0.9909999966621399},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7509999871253967},{"id":"https://openalex.org/keywords/dose-combination","display_name":"dose combination","score":0.5559999942779541},{"id":"https://openalex.org/keywords/hiv-protease-inhibitors","display_name":"HIV protease inhibitors","score":0.6600000262260437},{"id":"https://openalex.org/keywords/ritonavir-boosting","display_name":"ritonavir boosting","score":0.8220000267028809},{"id":"https://openalex.org/keywords/cyp3a4-inhibition","display_name":"CYP3A4 inhibition","score":0.7559999823570251},{"id":"https://openalex.org/keywords/steady-state-trough-concentration","display_name":"steady-state trough concentration","score":0.75},{"id":"https://openalex.org/keywords/self-emulsifying-drug-delivery-systems","display_name":"self-emulsifying drug delivery systems","score":0.8659999966621399},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4950000047683716}],"concepts":[{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.8883577585220337},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7974122166633606},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.771126925945282},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.593445897102356},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.48321735858917236},{"id":"https://openalex.org/C2781143361","wikidata":"https://www.wikidata.org/wiki/Q55761529","display_name":"Protease inhibitor (pharmacology)","level":5,"score":0.46898871660232544},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4470868408679962},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.16525548696517944},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.13469749689102173},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.09714546799659729},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.07986694574356079}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002214","descriptor_name":"Capsules","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004655","descriptor_name":"Emulsions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011753","descriptor_name":"Pyrones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011753","descriptor_name":"Pyrones","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011753","descriptor_name":"Pyrones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1310/rrx7-49me-27v7-mwwv","doi":"https://doi.org/10.1310/rrx7-49me-27v7-mwwv","is_oa":true,"landing_page_url":"https://doi.org/10.1310/rrx7-49me-27v7-mwwv","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1310/RRX7-49ME-27V7-MWWV?needAccess=true&role=button","source":{"id":"https://openalex.org/S13415641","display_name":"HIV Clinical Trials","issn_l":"1528-4336","issn":["1528-4336","1945-5771"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV Clinical Trials","raw_type":"journal-article"},{"id":"pmid:15682350","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15682350","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV clinical trials","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1310/rrx7-49me-27v7-mwwv","doi":"https://doi.org/10.1310/rrx7-49me-27v7-mwwv","is_oa":true,"landing_page_url":"https://doi.org/10.1310/rrx7-49me-27v7-mwwv","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1310/RRX7-49ME-27V7-MWWV?needAccess=true&role=button","source":{"id":"https://openalex.org/S13415641","display_name":"HIV Clinical Trials","issn_l":"1528-4336","issn":["1528-4336","1945-5771"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV Clinical Trials","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2011753619.pdf","grobid_xml":"https://content.openalex.org/works/W2011753619.grobid-xml"},"referenced_works_count":18,"referenced_works":["https://openalex.org/W1651794786","https://openalex.org/W1848709375","https://openalex.org/W1981719094","https://openalex.org/W1988525115","https://openalex.org/W2004293828","https://openalex.org/W2005104005","https://openalex.org/W2007041830","https://openalex.org/W2007788465","https://openalex.org/W2050508755","https://openalex.org/W2066735345","https://openalex.org/W2067274937","https://openalex.org/W2086783015","https://openalex.org/W2086911097","https://openalex.org/W2106571163","https://openalex.org/W2114339005","https://openalex.org/W2119441418","https://openalex.org/W2142869955","https://openalex.org/W2158884589"],"related_works":["https://openalex.org/W2083580679","https://openalex.org/W2062808593","https://openalex.org/W2171789625","https://openalex.org/W2138734727","https://openalex.org/W2127537255","https://openalex.org/W2050898053","https://openalex.org/W2140428625","https://openalex.org/W2009325269","https://openalex.org/W1988700071","https://openalex.org/W2065409000"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"characterize":[2],"the":[3,8,69,73,122,129,133,158],"steady-state":[4,92,137],"pharmacokinetic":[5],"combination":[6],"of":[7,42,79,114,121,128,188],"nonpeptidic":[9],"protease":[10,163],"inhibitor":[11],"tipranavir":[12],"(TPV)":[13],"with":[14,99,117,146],"ritonavir":[15],"(RTV)":[16],"in":[17,66,85,91,218],"95":[18],"healthy":[19],"adult":[20],"volunteers,":[21],"a":[22,86,110,170],"phase":[23,203],"1,":[24],"single-center,":[25],"open-label,":[26],"randomized,":[27],"parallel-group":[28],"trial":[29],"was":[30,108],"conducted.":[31],"METHOD:":[32],"Participants":[33],"received":[34,58],"250-mg":[35],"self-emulsifying":[36],"drug":[37],"delivery":[38],"system":[39],"(SEDDS)":[40],"capsules":[41],"TPV":[43,70,80,93,100,106,140,160,209],"at":[44,101],"doses":[45,131],"between":[46],"250":[47],"mg":[48,51,142,145,149,152],"and":[49,81,143],"1250":[50],"twice":[52],"daily":[53],"for":[54,72,139,162,173],"11":[55],"days,":[56],"then":[57],"one":[59,120],"or":[60,150],"two":[61],"RTV":[62,82,147],"100-mg":[63],"SEDDS":[64],"capsules,":[65,71],"addition":[67],"to":[68,155,215],"next":[74],"21":[75],"days.":[76],"RESULTS:":[77],"Coadministration":[78],"(TPV/r)":[83],"resulted":[84],"greater":[87],"than":[88],"20-fold":[89],"increase":[90],"trough":[94],"concentrations":[95,211],"(Cssmin)":[96],"as":[97],"compared":[98],"steady":[102],"state":[103],"alone.":[104],"Mean":[105],"Cssmin":[107,138],"above":[109],"preliminary":[111],"target":[112],"threshold":[113],"20":[115,154],"microM":[116],"all":[118,181],"but":[119],"RTV-boosted":[123,208],"doses;":[124],"without":[125],"boosting,":[126],"none":[127],"TPV-alone":[130],"exceeded":[132],"threshold.":[134],"The":[135,191],"average":[136],"500":[141],"750":[144],"100":[148],"200":[151],"were":[153,197],"57":[156],"times":[157],"protein-adjusted":[159],"IC90R49\\CCR418569)":[161],"inhibitor-resistant":[164],"HIV-1.":[165],"An":[166],"erythromycin":[167],"breath":[168],"test,":[169],"surrogate":[171],"marker":[172],"cytochrome":[174],"P450":[175],"isoenzyme":[176],"3A4":[177],"activity,":[178],"indicated":[179],"that":[180,207,212],"TPV/r":[182],"combinations":[183],"given":[184],"provided":[185],"net":[186],"inhibition":[187],"this":[189],"isoenzyme.":[190],"most":[192],"frequent":[193],"treatment-related":[194],"adverse":[195],"events":[196],"mild":[198],"gastrointestinal":[199],"symptoms.":[200],"CONCLUSION:":[201],"This":[202],"1":[204],"study":[205],"demonstrated":[206],"achieves":[210],"are":[213],"expected":[214],"be":[216],"effective":[217],"treating":[219],"drug-experienced":[220],"patients.":[221]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2011753619","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}
